Published Works by Our Team

  1.  ​Beaussant Y, Tarbi EC, Nigam K, et al.: Acceptability of Psilocybin-assisted Group Therapy in Patients with Cancer and Major Depressive Disorder: Qualitative Analysis. Cancer 2023
  2. Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, Stevens N, Richards B, Schor N, Honstein H, Jenkins B, Bates M, Thambi P. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2023 Dec 18. doi: 10.1002/cncr.35010. Epub ahead of print. PMID: 38105655.
  3. Bouchet L., Sager Z.S., Yrondi A., Nigam K., Anderson B., Ross S., Petridis P., and Beaussant, Y. Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review. Journal of Psychopharmacology 2023; In Press.
  4. Sholevar R, Peteet J, Sanders J, Beaussant Y. Disruption as an opportunity or threat: A qualitative analysis of factors influencing the attitudes of experts in serious illness care toward psychedelic-assisted therapies. Palliat Support Care. 2023 Oct 11:1-6. doi: 10.1017/S1478951523001475. Epub ahead of print. PMID: 37818641.
  5. Beaussant, Y., Nigam, K. Expending Perspectives on the Potential for Psychedelic-Assisted Therapies to Improve the Experience of Aging. Am J Geriatr Psychiatry 31, 54–57. 2023
  6. Nigam, K., Curseen, K., Beaussant, Y. Psychedelics and Related Pharmacotherapies as Integrative Medicine for Older Adults in Palliative Care. Clinics in Geriatric Medicine 39(3):423-436. 2023.
  7. Schipper S, Nigam K, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C. Psychedelic/entactogen‐assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care. Cochrane Database of Systematic Reviews 2022, Issue 11. Art. No.: CD015383.
  8. Ljuslin M, Nigam K, Sholevar R, Doerner Rinaldi A, Schipper S, Cloutier A, Sanders J, King F 4th, Beaussant Y. Psychedelic-Assisted Therapies in Patients With Serious Illness: Opportunities and Challenges. Psychiatric Annals, 2022;52(9):359–364. 
  9. De Oliveira Maia L, Beaussant Y, Mesquita Garcia AC. The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: a systematic review. Journal of Pain and Symptom Management. 2022.
  10. Rosa WE, Sager ZS, Miller M, Bernstein I, Doerner Rinaldi A, Addicott K, Ljuslin M, Adrian C, Back AL, Beachy J, Bossis AP, Breitbart WS, Cosimano MP, Fischer SM, Guss J, Knighton E, Phelps J, Richards BD, Richards WA, Tulsky JA, Williams PM and Beaussant Y. Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. J Palliat Med. 2022. In Press.
  11. Beaussant Y, Tulsky J, Guérin B, Schwarz-Plaschg C, Sanders JJ. Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness. J Palliat Med. 2021 Nov;24(11):1657-1666. PubMed PMID: 33848208.
  12. Barnett BS, Beaussant Y, King F 4th, Doblin R. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey. J Psychoactive Drugs. 2021 Aug 19; PubMed PMID: 34409921.
  13. Beaussant Y, Sanders J, Sager Z, Tulsky JA, Braun IM, Blinderman CD, Bossis AP, Byock I. Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives. J Palliat Med. 2020 Oct;23(10):1323-1334. PubMed PMID: 32233936. 

Press & Publicity
Photo credits, from top left clockwise: Comrade for Boston Magazine, Sam Ogen for DFCI, Jessica Rinaldi for Boston Globe, Ibrahim Rayintakath for NBC News, Sam Ogen for DFCI, Leigh Paterson/KUNC.​